Previous 10 | Next 10 |
Company Receives Notice of Allowance from U.S. Patent and Trademark Office IRVINE, CA / ACCESSWIRE / February 24, 2021 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI), a developer of medical devices that restore cardiac and vascular health, today announced that it has received a...
Capital Raise to Fund VenoValve U.S. Pivotal Trial IRVINE, CA / ACCESSWIRE / February 11, 2021 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI), a developer of medical devices that restore cardiac and vascular health, today announced that it has successfully completed a public of...
Gainers: Applied UV (AUVI) +367%.Comstock Holding Companies (CHCI) +125%.KalVista Pharmaceuticals (KALV) +112%.Veru (VERU) +60%.Heat Biologics (HTBX) +58%.SemiLEDs (LEDS) +45%.U.S. Well Services (USWS) +41%.Tilray (TLRY) +41%.Eastside Distilling (EAST) +40%.FSD Pharma (HUGE) +35%.Lo...
Gainers: KalVista Pharmaceuticals KALV +134%, Heat Biologics HTBX +70%, Iterum Therapeutics (ITRM) +48%, OrganiGram OGI +47%, Oragenics (OGEN) +24%.Losers: Aeterna Zentaris (AEZS) -27%, Ekso Bionics EKSO -23%, Ocugen OCGN -...
IRVINE, CA / ACCESSWIRE / February 9, 2021 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI), a developer of medical devices that restore cardiac and vascular health, today announced the pricing of its upsized underwritten public offering of units for gross proceeds of approximately $36 milli...
Acorda Therapeutics (ACOR) +54% after announcing agreement for sale of manufacturing operations and long-term global supply agreement.Summit Midstream Partners (SMLP) +45% after winning FERC construction OK.WiMi Hologram Cloud (WIMI) +38% on obtaining a patent for a 3D holograp...
Company to Move Forward with Application for VenoValve U.S. Pivotal Trial IRVINE, CA / ACCESSWIRE / January 12, 2021 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI), a developer of medical devices that restore cardiac and vascular health, today announced that it has successfully con...
Hancock Jaffe Laboratories (HJLI) promoted Dr. Hamed Alavi to Vice President of Research and Development and Quality and Mr. Craig Glynn as permanent CFO.Dr. Alavi, most recently served as the Director of Research and Development and Quality. Mr. Glynn since April 2020 ser...
IRVINE, CA / ACCESSWIRE / December 30, 2020 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI), a developer of medical devices that restore cardiac and vascular health, today announced that Dr. Hamed Alavi has been promoted to Vice President of Research and Development and Quality and that C...
Company Regains Compliance with NASDAQ Minimum Bid Requirement IRVINE, CA / ACCESSWIRE / December 21, 2020 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI), a developer of medical devices that restore cardiac and vascular health, today announced that the Company has received formal n...
News, Short Squeeze, Breakout and More Instantly...
Hancock Jaffe Laboratories Inc. Company Name:
HJLI Stock Symbol:
NASDAQ Market:
Company Now Trading Under Ticker Symbol "NVNO" IRVINE, CA / ACCESSWIRE / October 1, 2021 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, announced today that it has successfully comple...
Live webinar followed by Q&A on Monday, September 27 th at 1:00 PM ET with Robert Berman Chief Executive Officer of Hancock Jaffe Laboratories IRVINE, CA / ACCESSWIRE / September 24, 2021 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI) ("Hancock Jaffe" or the "Company"), a medic...
- Hancock Jaffe changing name to enVVeno Medical Corporation and ticker symbol to NASDAQ: NVNO, effective October 1, 2021 - - Development strategy to focus on venous disease and advancement of the VenoValve® - - Initiated development of second product for the treatment of veno...